
Cardiol Therapeutics (CRDL) Stock Forecast & Price Target
Cardiol Therapeutics (CRDL) Analyst Ratings
Bulls say
Cardiol Therapeutics is poised for success due to the positive results of their CardiolRx program, with statistically significant improvement in left ventricular mass and a clean safety profile that reinforces its potential. Additionally, the failure of AstraZeneca's AZD3427 highlights the potential of Cardiol's alternative, non-vasodilatory approach to treating heart failure with their CRD-38 program, which has shown potential for improving LV mass and its underlying components. Coupled with promising preclinical studies and a strong valuation, Cardiol presents a lucrative investment opportunity.
Bears say
Cardiol Therapeutics is currently undervalued with a market capitalization of only $98M, as investors are not fully aware of the positive signals from the ARCHER and MAVERIC trials, which demonstrate the potential of their lead candidate CardiolRx in treating recurrent pericarditis and myocarditis. Furthermore, the ongoing development of CRD-38 offers additional potential and strengthens the company's portfolio.
This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cardiol Therapeutics (CRDL) Analyst Forecast & Price Prediction
Start investing in Cardiol Therapeutics (CRDL)
Order type
Buy in
Order amount
Est. shares
0 shares